Thiotepa-melphalan myeloablative therapy for high-risk neuroblastoma

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Therapeutics

Background:

• High-dose chemotherapy (HDC) for high-risk neuroblastoma lacks established optimal regimens.
• A specific HDC regimen using thiotepa and melphalan is utilized in Japan.
• This regimen involves two cycles with specific cumulative doses of thiotepa (800 mg/m²) and melphalan (280 mg/m²).

Purpose of the Study:

• To assess the safety and efficacy of the thiotepa-melphalan HDC regimen.
• To evaluate outcomes in patients with high-risk neuroblastoma treated with this regimen.
• To identify prognostic factors influencing treatment success.

Main Methods:

• Retrospective review of 41 high-risk neuroblastoma patients treated between 2002 and 2012.
• Patients received thiotepa-melphalan HDC followed by autologous peripheral blood stem cell rescue.
• Analysis included MYCN amplification status and outcomes like event-free survival (EFS) and overall survival.

Main Results:

• The 5-year event-free survival (EFS) was 41.5% and overall survival was 56.1%.
• MYCN-amplified neuroblastoma showed significantly better 5-year EFS (60.9%) compared to MYCN-nonamplified (16.7%).
• MYCN amplification emerged as a favorable prognostic factor; regimen-related toxicity caused three deaths.

Conclusions:

• Thiotepa-melphalan high-dose therapy shows potential efficacy for high-risk neuroblastoma.
• The regimen's toxicity necessitates careful clinical management and monitoring.
• MYCN amplification status is a critical factor in predicting treatment outcomes.